Hizentra initially received EMA approval in 2011 as a 20%, once weekly SCIg replacement therapy for adults and children with PID to help treat existing or chronic infections and prevent new infections from occurring.
http://www.businesswire.com/news/home/20131205005486/en/European-Medicines-Agency-Approves-Weeks-Dosing-Option
http://www.businesswire.com/news/home/20131205005486/en/European-Medicines-Agency-Approves-Weeks-Dosing-Option
No comments:
Post a Comment